New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
07:38 EDTHZNPHorizon Pharma to receive approval from UK MHRA
Horizon Pharma announced that the United Kingdom Medicines and Healthcare products Regulatory Agency, or MHRA, based on the favorable recommendation of their Commission on Human Medicines (CHM), will grant a Marketing Authorization for Duexis, pending review of updated licensing documents which the Company has provided to the MHRA. The MA of Duexis is for the treatment of osteoarthritis, or OA, rheumatoid arthritis, or RA, and ankylosing spondylitis, or AS, and to decrease the risk of developing upper gastrointestinal ulcers. Duexis is approved and available in the United States.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
07:45 EDTHZNPHorizon Pharma to host conference call
Subscribe for More Information
07:04 EDTHZNPHorizon Pharma acquires U.S. rights to PENNSAID 2% for $45M
Subscribe for More Information
October 13, 2014
17:06 EDTHZNPHorizon Pharma: Actimmune net sales potential $500M with FDA approval for FA
Subscribe for More Information
05:31 EDTHZNPHorizon Pharma to host analyst day
Analyst Day to be held in King of Prussia, PA on October 13 at 5 pm. Webcast Link
October 9, 2014
15:31 EDTHZNPHorizon Pharma's Actimmune Phase 2 results provide more growth, says Avondale
Avondale said Horizon Pharma's Actimmune Phase 2 results were strong and support incremental annual market opportunity of approximately $300K per year. The firm views the results as another potential growth driver and its Outperform rating and $22 price target.
13:40 EDTHZNPHorizon Pharma presents ACTIMMUNE Phase 2 data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use